VolitionRx (NYSE:VNRX) Stock Rating Upgraded by Jones Trading

Jones Trading upgraded shares of VolitionRx (NYSE:VNRX) to a strong-buy rating in a report released on Tuesday morning, MarketBeat reports. They currently have $3.00 price objective on the stock.

Several other brokerages have also recently issued reports on VNRX. D. Boral Capital reissued a “buy” rating and issued a $5.00 price objective on shares of VolitionRx in a report on Wednesday, April 30th. Wall Street Zen assumed coverage on VolitionRx in a report on Thursday, May 15th. They issued a “sell” rating for the company. Finally, HC Wainwright began coverage on VolitionRx in a report on Tuesday, April 8th. They issued a “buy” rating and a $2.50 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $3.50.

VolitionRx Stock Up 6.0%

Shares of VNRX stock opened at $0.60 on Tuesday. The stock has a market cap of $61.40 million, a PE ratio of -1.66 and a beta of 1.07. The business has a 50-day simple moving average of $0.50 and a 200-day simple moving average of $0.57. VolitionRx has a 52-week low of $0.40 and a 52-week high of $0.90.

Insider Activity at VolitionRx

In other news, CEO Cameron John Reynolds acquired 181,818 shares of the business’s stock in a transaction on Wednesday, March 26th. The stock was bought at an average cost of $0.55 per share, for a total transaction of $99,999.90. Following the purchase, the chief executive officer now owns 2,299,222 shares in the company, valued at approximately $1,264,572.10. This represents a 8.59% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders acquired a total of 271,818 shares of company stock worth $141,100 in the last 90 days. Corporate insiders own 10.40% of the company’s stock.

Institutional Investors Weigh In On VolitionRx

Several large investors have recently bought and sold shares of VNRX. Two Sigma Securities LLC purchased a new stake in VolitionRx during the 4th quarter worth approximately $29,000. Northern Trust Corp increased its stake in VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after buying an additional 28,579 shares in the last quarter. Lagoda Investment Management L.P. increased its stake in VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after buying an additional 1,481,000 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in VolitionRx during the 4th quarter worth approximately $36,000. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.